Paul M. McKie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul M. McKie has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- John C. Burnett
Mayo Clinic
22 shared publications Alessandro Cataliotti
Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN
19 shared publications- Horng H. Chen
Department of Cardiovascular Medicine, Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN (F.W.A., J.S., J.C.M., X.M., H.H.C.).
15 shared publications S. Jeson Sangaralingham
Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN
13 shared publicationsJohn C. Burnett
Mayo Clinic and Foundation
12 shared publications- Tomoko Ichiki
Mayo Clinic, Rochester, MN
9 shared publications
Latest Publications
- 1 December 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (12) , e011761
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial
BACKGROUND: Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF. METHODS: This open-label study included 67 patients hospitalized with acute HF and renal dysfunction. Patients were randomized to standard care, low-dose intravenous BNP (0.005 µg/kg per minute), or combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours. The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours. RESULTS: Treatment with BNP and BNP/PDEV inhibitor significantly increased plasma cGMP at 24 hours (+25.6% [+9.8%, +84.7%] and +60.8% [+32.3%, +103.8%] for BNP and BNP/PDEV versus −13.5% [−29.1%, +14.2%] with standard care; P =0.001). However, there was no significant change in estimated glomerular filtration rate 0 (−10.8%, +12.7%) for standard care versus 0 (−15.3%, +11.8%) for the BNP group versus –8.8% (−14.3%, +8.3%) for the BNP/PDEV group ( P =0.60) or blood urea nitrogen −1.4% (−10.7%, +12.0%) for standard care versus –5.9% (−14.6%, +9.4%) for the BNP group versus +6.9% (−5.3%, +18.8%) for the BNP/PDEV group ( P =0.38) between groups. Hypotension was more common in the BNP/PDEV inhibitor group. CONCLUSIONS: BNP and combination BNP/PDEV inhibition increased plasma cGMP in patients with acute HF but did not improve renal function or urinary sodium/cGMP excretion. Our study does not support the use of intravenous low-dose BNP with or without PDEV inhibition to enhance renal function in patients admitted with acute HF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00972569.
- 1 December 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (12) , e011761
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial
BACKGROUND: Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF. METHODS: This open-label study included 67 patients hospitalized with acute HF and renal dysfunction. Patients were randomized to standard care, low-dose intravenous BNP (0.005 µg/kg per minute), or combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours. The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours. RESULTS: Treatment with BNP and BNP/PDEV inhibitor significantly increased plasma cGMP at 24 hours (+25.6% [+9.8%, +84.7%] and +60.8% [+32.3%, +103.8%] for BNP and BNP/PDEV versus −13.5% [−29.1%, +14.2%] with standard care; P =0.001). However, there was no significant change in estimated glomerular filtration rate 0 (−10.8%, +12.7%) for standard care versus 0 (−15.3%, +11.8%) for the BNP group versus –8.8% (−14.3%, +8.3%) for the BNP/PDEV group ( P =0.60) or blood urea nitrogen −1.4% (−10.7%, +12.0%) for standard care versus –5.9% (−14.6%, +9.4%) for the BNP group versus +6.9% (−5.3%, +18.8%) for the BNP/PDEV group ( P =0.38) between groups. Hypotension was more common in the BNP/PDEV inhibitor group. CONCLUSIONS: BNP and combination BNP/PDEV inhibition increased plasma cGMP in patients with acute HF but did not improve renal function or urinary sodium/cGMP excretion. Our study does not support the use of intravenous low-dose BNP with or without PDEV inhibition to enhance renal function in patients admitted with acute HF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00972569.
- 7 June 2023
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 29 (10) , 1461-1465
The Cardiorenal Effects of Chronic Phosphodiesterase-V Inhibition in Preclinical Diastolic Dysfunction (Stage B Heart Failure)
- 7 June 2023
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 29 (10) , 1461-1465
The Cardiorenal Effects of Chronic Phosphodiesterase-V Inhibition in Preclinical Diastolic Dysfunction (Stage B Heart Failure)
- 1 October 2021
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (10) , 2576-2586
Artificial Intelligence–Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population
- 1 October 2021
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 96 (10) , 2576-2586
Artificial Intelligence–Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population
- Open Access
- 1 June 2021
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 6 (6) , 497-504
STOP-HF Trial
- 1 June 2021
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 6 (6) , 497-504
Open AccessSTOP-HF Trial
- Open Access
- 1 October 2020
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 10 (5) , 388-395
Synchronous neurology–primary care collaboration in a medical home
Background Synchronous collaboration as defined by a simultaneous encounter between primary care providers (PCPs), patients, and neurologists may improve access to neurologic expertise, care value, and satisfaction of PCPs and patients. We examined a series of synchronous collaborations and report outcomes, PCP satisfaction, downstream utilization, and illustrative case examples. Methods Within an outpatient collaborative primary care–neurology care model, we implemented synchronous video consultations from a central hub to satellite clinics while increasing availability of synchronous telephone and face-to-face collaboration. PCP experience was assessed by a postcollaboration survey. Individual cases were summarized. Clinical and utilization outcomes were assessed by a neurologist immediately after and by follow-up chart review. Results A total of 58 total synchronous collaborations were performed: 30 by telephone (52%), 18 face to face (31%), and 10 by video (17%) over 27 clinic half-days. The most frequent outcomes as assessed by the neurologist were reassurance of the PCP (23/58; 40%) and patient (22/59; 38%), and the neurologist changed the treatment plan (23/58; 40%). A subsequent face-to-face consultation was completed in 15% (6/58) of patients initially assessed by telephone or video. Test utilization was avoided in 40% (23/58). Unintended utilization occurred 9% (5/58). Most PCPs were very satisfied with the ease of access, quality of care, and reported high likelihood of subsequent use. PCPs perceived similar or less time spent during synchronous vs asynchronous collaboration and neurologist usually altered the testing (87.8%) and treatment plan (95.2%). Conclusions Synchronous collaboration between neurologists and PCPs may improve timely access to neurologic expertise, downstream utilization, and PCP satisfaction.
- 1 October 2020
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 10 (5) , 388-395
Open AccessSynchronous neurology–primary care collaboration in a medical home
Background Synchronous collaboration as defined by a simultaneous encounter between primary care providers (PCPs), patients, and neurologists may improve access to neurologic expertise, care value, and satisfaction of PCPs and patients. We examined a series of synchronous collaborations and report outcomes, PCP satisfaction, downstream utilization, and illustrative case examples. Methods Within an outpatient collaborative primary care–neurology care model, we implemented synchronous video consultations from a central hub to satellite clinics while increasing availability of synchronous telephone and face-to-face collaboration. PCP experience was assessed by a postcollaboration survey. Individual cases were summarized. Clinical and utilization outcomes were assessed by a neurologist immediately after and by follow-up chart review. Results A total of 58 total synchronous collaborations were performed: 30 by telephone (52%), 18 face to face (31%), and 10 by video (17%) over 27 clinic half-days. The most frequent outcomes as assessed by the neurologist were reassurance of the PCP (23/58; 40%) and patient (22/59; 38%), and the neurologist changed the treatment plan (23/58; 40%). A subsequent face-to-face consultation was completed in 15% (6/58) of patients initially assessed by telephone or video. Test utilization was avoided in 40% (23/58). Unintended utilization occurred 9% (5/58). Most PCPs were very satisfied with the ease of access, quality of care, and reported high likelihood of subsequent use. PCPs perceived similar or less time spent during synchronous vs asynchronous collaboration and neurologist usually altered the testing (87.8%) and treatment plan (95.2%). Conclusions Synchronous collaboration between neurologists and PCPs may improve timely access to neurologic expertise, downstream utilization, and PCP satisfaction.
- 1 June 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (6) , 750-756.e2
Computerized Advisory Decision Support for Cardiovascular Diseases in Primary Care: A Cluster Randomized Trial
- 1 June 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (6) , 750-756.e2
Computerized Advisory Decision Support for Cardiovascular Diseases in Primary Care: A Cluster Randomized Trial
- Open Access
- 1 December 2019
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (4) , 476-482
Getting to the Heart of the Matter: A Triage Model to Improve Utilization of Cardiology Consultative Services
- 1 December 2019
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 3 (4) , 476-482
Open AccessGetting to the Heart of the Matter: A Triage Model to Improve Utilization of Cardiology Consultative Services
- Top Cited Papers
- 7 January 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (1) , 70-74
Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram
Asymptomatic left ventricular dysfunction (ALVD) is present in 3-6% of the general population, is associated with reduced quality of life and longevity, and is treatable when found1-4. An inexpensive, noninvasive screening tool for ALVD in the doctor's office is not available. We tested the hypothesis that application of artificial intelligence (AI) to the electrocardiogram (ECG), a routine method of measuring the heart's electrical activity, could identify ALVD. Using paired 12-lead ECG and echocardiogram data, including the left ventricular ejection fraction (a measure of contractile function), from 44,959 patients at the Mayo Clinic, we trained a convolutional neural network to identify patients with ventricular dysfunction, defined as ejection fraction ≤35%, using the ECG data alone. When tested on an independent set of 52,870 patients, the network model yielded values for the area under the curve, sensitivity, specificity, and accuracy of 0.93, 86.3%, 85.7%, and 85.7%, respectively. In patients without ventricular dysfunction, those with a positive AI screen were at 4 times the risk (hazard ratio, 4.1; 95% confidence interval, 3.3 to 5.0) of developing future ventricular dysfunction compared with those with a negative screen. Application of AI to the ECG-a ubiquitous, low-cost test-permits the ECG to serve as a powerful screening tool in asymptomatic individuals to identify ALVD.
- 7 January 2019
- Published by Springer Nature in Nature Medicine
- Vol. 25 (1) , 70-74
Top Cited PapersScreening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram
Asymptomatic left ventricular dysfunction (ALVD) is present in 3-6% of the general population, is associated with reduced quality of life and longevity, and is treatable when found1-4. An inexpensive, noninvasive screening tool for ALVD in the doctor's office is not available. We tested the hypothesis that application of artificial intelligence (AI) to the electrocardiogram (ECG), a routine method of measuring the heart's electrical activity, could identify ALVD. Using paired 12-lead ECG and echocardiogram data, including the left ventricular ejection fraction (a measure of contractile function), from 44,959 patients at the Mayo Clinic, we trained a convolutional neural network to identify patients with ventricular dysfunction, defined as ejection fraction ≤35%, using the ECG data alone. When tested on an independent set of 52,870 patients, the network model yielded values for the area under the curve, sensitivity, specificity, and accuracy of 0.93, 86.3%, 85.7%, and 85.7%, respectively. In patients without ventricular dysfunction, those with a positive AI screen were at 4 times the risk (hazard ratio, 4.1; 95% confidence interval, 3.3 to 5.0) of developing future ventricular dysfunction compared with those with a negative screen. Application of AI to the ECG-a ubiquitous, low-cost test-permits the ECG to serve as a powerful screening tool in asymptomatic individuals to identify ALVD.
- Open Access
- 2 September 2015
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 16 (S1) , A3
MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
- 2 September 2015
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 16 (S1) , A3
Open AccessMANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results